CN102037136A - 用于诊断、预防和/或护理特征为β-淀粉和/或淀粉样物质在人和/或动物器官和组织中异常沉积的人和/或动物病理的产物及它们的应用、和用于确定这种病理风险的筛选方法 - Google Patents

用于诊断、预防和/或护理特征为β-淀粉和/或淀粉样物质在人和/或动物器官和组织中异常沉积的人和/或动物病理的产物及它们的应用、和用于确定这种病理风险的筛选方法 Download PDF

Info

Publication number
CN102037136A
CN102037136A CN2008801213173A CN200880121317A CN102037136A CN 102037136 A CN102037136 A CN 102037136A CN 2008801213173 A CN2008801213173 A CN 2008801213173A CN 200880121317 A CN200880121317 A CN 200880121317A CN 102037136 A CN102037136 A CN 102037136A
Authority
CN
China
Prior art keywords
app
people
fragment
pathology
amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801213173A
Other languages
English (en)
Chinese (zh)
Inventor
G·迪费德
M·莫斌
F·塔格利维尼
A·马蒂尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FOND I R C C S ISTITUTO NEUROL
Original Assignee
FOND I R C C S ISTITUTO NEUROL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FOND I R C C S ISTITUTO NEUROL filed Critical FOND I R C C S ISTITUTO NEUROL
Publication of CN102037136A publication Critical patent/CN102037136A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Environmental Sciences (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
CN2008801213173A 2007-10-12 2008-10-10 用于诊断、预防和/或护理特征为β-淀粉和/或淀粉样物质在人和/或动物器官和组织中异常沉积的人和/或动物病理的产物及它们的应用、和用于确定这种病理风险的筛选方法 Pending CN102037136A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2007A001975 2007-10-12
IT001975A ITMI20071975A1 (it) 2007-10-12 2007-10-12 Prodotti e loro uso per la diagnosi prevenzione e-o cura di patologie umane e-o animali caraterizzate dalla anomala deposizione di sostanza b-amiloide e-o similamiloide in organi e tesstui umani e-o animali e metodo di screening per la determinazione
PCT/EP2008/008595 WO2009047002A2 (en) 2007-10-12 2008-10-10 Products and their use for the diagnosis, prevention, and/or care of human and/or animal pathologies characterised by the anomalous deposition of b-amyloid and/or amyloid-like substance in human and/or animal organs and tissues, and screening method for determining the risk of such pathologies

Publications (1)

Publication Number Publication Date
CN102037136A true CN102037136A (zh) 2011-04-27

Family

ID=40313814

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801213173A Pending CN102037136A (zh) 2007-10-12 2008-10-10 用于诊断、预防和/或护理特征为β-淀粉和/或淀粉样物质在人和/或动物器官和组织中异常沉积的人和/或动物病理的产物及它们的应用、和用于确定这种病理风险的筛选方法

Country Status (7)

Country Link
US (1) US20110010785A1 (enExample)
EP (1) EP2220251B1 (enExample)
JP (1) JP2011500007A (enExample)
CN (1) CN102037136A (enExample)
ES (1) ES2607897T3 (enExample)
IT (1) ITMI20071975A1 (enExample)
WO (1) WO2009047002A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102943126A (zh) * 2012-12-12 2013-02-27 芮屈生物技术（上海）有限公司 老年性痴呆病变前期APP基因mRNA水平原位杂交筛查试剂盒及筛查方法和应用
CN106574930A (zh) * 2014-05-22 2017-04-19 株式会社岛津制作所 评价脑内的淀粉样蛋白β肽蓄积状态的替代性生物标记物和其分析方法
CN107849608A (zh) * 2015-04-30 2018-03-27 江苏挪贝肽医药科技有限公司 一种筛选用于治疗阿尔茨海默病的药物和治疗靶点的方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010001198A1 (de) * 2010-01-26 2011-07-28 Robert Bosch GmbH, 70469 Verfahren zur Identifikation von Verbrauchern bzw. Erzeugern in einem pneumatischen, hydraulischen oder elektrischen Netz
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
JP5650249B2 (ja) * 2011-01-07 2015-01-07 セイコーエプソン株式会社 アミロイド前駆体タンパク質のシグナルペプチドに対する抗体
WO2013180011A1 (ja) 2012-05-28 2013-12-05 東亞合成株式会社 抗菌ペプチド及びその利用
WO2014061749A1 (ja) 2012-10-18 2014-04-24 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用
DE102013201324B4 (de) 2013-01-28 2024-05-16 Aktiebolaget Skf Verfahren zum Bestimmen einer Lagervorspannung
US20160011616A1 (en) * 2014-07-11 2016-01-14 Microsoft Technology Licensing, Llc Power management
CN109776665B (zh) * 2019-02-02 2021-02-05 首都医科大学宣武医院 阿尔茨海默病新突变、其稳转细胞模型及医药用途
IT201900010722A1 (it) * 2019-07-02 2021-01-02 Fondazione Irccs St Neurologico Carlo Besta Composto e composizione per il trattamento multi-obiettivo di disturbi legati alla proteina tau
EP4262846A4 (en) * 2020-12-18 2024-11-20 Baylor College of Medicine ADMINISTRATION OF ABETA VARIANTS FOR INHIBITION OF AGGREGATION

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7196163B2 (en) * 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
US20050106731A1 (en) * 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
BRPI0610093A2 (pt) * 2005-05-05 2008-12-09 Merck & Co Inc composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente
MX2008006957A (es) * 2005-11-30 2008-10-20 Abbott Lab Metodos para la preparacion de formas recombinantes de proteina beta-amiloide humana y usos de estas proteinas.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102943126A (zh) * 2012-12-12 2013-02-27 芮屈生物技术（上海）有限公司 老年性痴呆病变前期APP基因mRNA水平原位杂交筛查试剂盒及筛查方法和应用
CN106574930A (zh) * 2014-05-22 2017-04-19 株式会社岛津制作所 评价脑内的淀粉样蛋白β肽蓄积状态的替代性生物标记物和其分析方法
CN106574930B (zh) * 2014-05-22 2019-09-03 株式会社岛津制作所 评价脑内的淀粉样蛋白β肽蓄积状态的替代性生物标记物和其分析方法
CN107849608A (zh) * 2015-04-30 2018-03-27 江苏挪贝肽医药科技有限公司 一种筛选用于治疗阿尔茨海默病的药物和治疗靶点的方法

Also Published As

Publication number Publication date
ITMI20071975A1 (it) 2009-04-13
ES2607897T3 (es) 2017-04-04
JP2011500007A (ja) 2011-01-06
US20110010785A1 (en) 2011-01-13
EP2220251A2 (en) 2010-08-25
EP2220251B1 (en) 2016-08-03
WO2009047002A3 (en) 2009-08-06
WO2009047002A2 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
CN102037136A (zh) 用于诊断、预防和/或护理特征为β-淀粉和/或淀粉样物质在人和/或动物器官和组织中异常沉积的人和/或动物病理的产物及它们的应用、和用于确定这种病理风险的筛选方法
Kim et al. MyD88-5 links mitochondria, microtubules, and JNK3 in neurons and regulates neuronal survival
Lim et al. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain
Kovacs et al. Alzheimer–associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells
Hadano et al. Mice deficient in the Rab5 guanine nucleotide exchange factor ALS2/alsin exhibit age-dependent neurological deficits and altered endosome trafficking
US7507798B2 (en) Antibody specific for mutant presenilin 1
Tadenev et al. Model validity for preclinical studies in precision medicine: precisely how precise do we need to be?
Cartier et al. A frameshift mutation in the γE–crystallin gene of the Elo mouse
Jiang et al. Targeted disruption of Nphp1 causes male infertility due to defects in the later steps of sperm morphogenesis in mice
JP2000506375A (ja) アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
JPH0767650A (ja) アルツハイマー病用のモデルとしての遺伝子交換性ハツカネズミ中の表示用組み換え型ａｐｐ小遺伝子
JP2004261187A (ja) アルツハイマー病に関するモデル
JP2022510341A (ja) 神経の疾患を検出し、予防し、回復に向かわせ、治療する方法
US6452065B2 (en) Transgenic mouse expressing non-native wild-type and familial Alzheimer's Disease mutant presenilin 1 protein on native presenilin 1 null background
JPH10500842A (ja) ユビキチン結合酵素をコードするｄｎａ
US6664443B1 (en) Pathogenic Tau mutations in transgenic mice
JP2000516087A (ja) アルツハイマー病に関連する遺伝子配列およびタンパク質、ならびにその使用
US20130133090A1 (en) Transgenic mammalls modified in bri protein expression
US6998467B1 (en) Antibody specific for presenilin 1 and method of use thereof
Guo et al. Par-4 in neuronal death and survival in Alzheimer’s disease and other neurogenerative diseases
JP4018304B2 (ja) 高親和性コリントランスポーター
US11895993B2 (en) Method of producing a novel animal model for tauopathies
Price et al. Selected genetically engineered models relevant to human neurodegenerative disease
Howng A phenotype-driven genetics screen identifies zinc finger protein 191 (Zfp191) as necessary for central nervous system myelination
Yang Presenilin structure, function and role in Alzheimer disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110427